Well, we see that the "wild card" is being played. Two more share placements to private investors on most advantageous terms that beats even the GEM deal.
Yesterday, a bit of a spark of interest when there were sales to clear out the buyers at .013 (for a little while). Then 4 sellers of 1,000,000 or more each jump in to hold down the price, then a single sale of 1,000,000 at a price of .011 at 12.11.54 today causing a few more to shake out at .011. And then at luch time, 13.07 we see why. A share placement "expected to be" at .012 plus options for 1/8 at .001. At this rate it will be a share placement at .01. The investors who came up with dollars earlier in the year at .013 & .014 may be feeling just a little bit miffed (unless of course these issues are also to them)!
BRR, I'm close to joining your camp! Why on earth don't they come clean? If they are going to offer such advantageous deals why not offer them to all current investors? Why do this when the GEM offer is already there to draw down on and sufficient for some time to come? Is there some kind of old mates deal going on here? Is this going to happen every month or so? And how can they justify a retrospective calculation of the price of issued shares after they have been issued, particularly when they know the sp is so fragile and subject to easy manipulation for very small dollar value sales and purchases.
The GEM deal was probably a matter of necessity at the time, but these are just over the top.
A full explanation of this should be required of the chairman.
- Forums
- ASX - By Stock
- MST
- analysis of top 20 changes & conclusions
analysis of top 20 changes & conclusions, page-10
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MST (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online